Ozdemir, OzerOzdemir, PelinVeral, AliUluer, HaticeOzhan, Mustafa Hikmet2019-10-272019-10-2720131513-7368https://doi.org/10.7314/APJCP.2013.14.8.4679https://hdl.handle.net/11454/46895Background: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its expression is indeed associated with clinical outcomes in advanced stage NSCLC patients. Materials and Methods: Pretreatment tumor biopsy samples of 83 stage 3B and 4 non-small cell lung cancer patients treated with platinum based chemotherapy were retrospectively analyzed for immunohistochemical ERCC1 expression. None of the patients received curative surgery or radiotherapy. Results: By calculating H- scores regarding the extent and intensity of immunohistochemical staining of tumor biopsy samples, ERCC1 expression was found to be positive in 50 patients (60.2%). ERCC1 positive and negative groups had no statistically significant differences regarding treatment response, progression free survival and overall survival (respectively p=0.161; p=0.412; p=0.823). Conclusions: In our study we found no association between ERCC1 expression and survival or treatment response. The study has some limitations, such as small sample size and retrospective analysis method. There is need of more knowledge for use of ERCC1 guided chemotherapy regimens in advanced stage NSCLC.en10.7314/APJCP.2013.14.8.4679info:eu-repo/semantics/openAccessNon-small cell lung cancerlung cancer chemotherapyERCC1molecular markersArticle14846794683WOS:00032827180003724083725Q3Q4